Eli Lilly and Company (NYSE:LLY) Shares Acquired by Intact Investment Management Inc.

Intact Investment Management Inc. increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 27.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,580 shares of the company’s stock after purchasing an additional 560 shares during the period. Intact Investment Management Inc.’s holdings in Eli Lilly and Company were worth $2,286,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Northeast Investment Management raised its stake in shares of Eli Lilly and Company by 1.5% in the 3rd quarter. Northeast Investment Management now owns 51,252 shares of the company’s stock valued at $45,406,000 after purchasing an additional 778 shares in the last quarter. Roman Butler Fullerton & Co. raised its stake in shares of Eli Lilly and Company by 1.2% in the 3rd quarter. Roman Butler Fullerton & Co. now owns 10,027 shares of the company’s stock valued at $9,158,000 after purchasing an additional 122 shares in the last quarter. Ground Swell Capital LLC acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $260,000. Kanawha Capital Management LLC raised its stake in shares of Eli Lilly and Company by 9.5% in the 3rd quarter. Kanawha Capital Management LLC now owns 2,280 shares of the company’s stock valued at $2,020,000 after purchasing an additional 198 shares in the last quarter. Finally, KG&L Capital Management LLC raised its stake in shares of Eli Lilly and Company by 4.0% in the 3rd quarter. KG&L Capital Management LLC now owns 4,733 shares of the company’s stock valued at $4,193,000 after purchasing an additional 182 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent analyst reports. Truist Financial upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday, September 16th. Barclays dropped their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Guggenheim increased their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,008.41.

Eli Lilly and Company Trading Down 1.6 %

Shares of NYSE LLY opened at $806.14 on Tuesday. Eli Lilly and Company has a 1-year low of $561.65 and a 1-year high of $972.53. The company has a market cap of $765.28 billion, a PE ratio of 87.15, a P/E/G ratio of 3.13 and a beta of 0.43. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 2.03. The company has a 50-day moving average of $908.15 and a two-hundred day moving average of $867.39.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company’s quarterly revenue was up 20.4% on a year-over-year basis. During the same period last year, the firm earned $0.10 earnings per share. As a group, equities analysts expect that Eli Lilly and Company will post 13.23 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.